CAMBRIDGE -
The equity awards were approved in accordance with Nasdaq Listing Rule 5635(4).
The employees received, in the aggregate, options to purchase 19,200 shares of Sarepta's common stock, and in the aggregate 10,000 restricted stock units ('RSUs'). The options have an exercise price of
One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date.
About
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Contact:
Tel: 617-274-4052
Email: iestepan@sarepta.com
(C) 2023 Electronic News Publishing, source